Synthetic astaxanthin is significantly inferior to algal-based astaxanthin as an antioxidant and may not be suitable as a human nutraceutical supplement
- 497 Downloads
Synthetic astaxanthin (S-AX) was tested against natural astaxanthin from Haematococcus pluvialis microalgae (N-AX) for antioxidant activity. In vitro studies conducted at Creighton University and Brunswick Laboratories showed N-AX to be over 50 times stronger than S-AX in singlet oxygen quenching and approximately 20 times stronger in free radical elimination. N-AX has been widely used over the last 15 years as a human nutraceutical supplement after extensive safety data and several health benefits were established. S-AX, which is synthesised from petrochemicals, has been used as a feed ingredient, primarily to pigment the flesh of salmonids. S-AX has never been demonstrated to be safe for use as a human nutraceutical supplement and has not been tested for health benefits in humans. Due to safety concerns with the use of synthetic forms of other carotenoids such as canthaxanthin and beta-carotene in humans, the authors recommend against the use of S-AX as a human nutraceutical supplement until extensive, long-term safety parameters have been established and human clinical trials have been conducted showing potential health benefits. Additionally, differences in various other properties between SAX and N-AX such as stereochemistry, esterification and the presence of supporting naturally occurring carotenoids in N-AX are discussed, all of which elicit further questions as to the safety and potential health benefits of S-AX. Ultimately, should S-AX prove safe for direct human consumption, dosage levels roughly 20–30 times greater than N-AX should be used as a result of the extreme difference in antioxidant activity between the two forms.
Keywordsastaxanthin synthetic astaxanthin natural astaxanthin antioxidant Haematococcus
Unable to display preview. Download preview PDF.
- 1.Capelli B, Cysewski G (2012) The world’s best kept health secret: natural astaxanthin. Cyanotech Corporation, Kailua-Kona, HIGoogle Scholar
- 2.Shiratori K, Ogami K, Nitta T (2005) The effects of astaxanthin on accommodation and asthenopia: efficacy identification study in healthy volunteers. J Clin Med 21(6):637–650Google Scholar
- 5.Savouré N, Briand G, Amory-Touz M, Combre A, Maudet M (1995) Vitamin A status and metabolism of cutaneous polyamines in the hairless mouse after UV irradiation: action of beta-carotene and astaxanthin. Int J Vitam Nutr Res 65(2):79–86Google Scholar
- 6.Yamashita E (2006) The effects of a dietary supplement containing astaxanthin on skin condition. Carotenoid Sci (10):91–95Google Scholar
- 7.Lee S, Bai S, Lee K, Namkoong S, Na H, Ha K, Han J, Yim S, Chang K, Kwon Y, Lee S, Kim Y (2003) Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing IkB kinase-dependent NFR-kB activation. Mol Cells 16(1):97–105Google Scholar
- 11.Bagchi D, Das DK, Engelman RM, Prasad MR, Subramanian R (1990) Polymorphonuclear leucocytes as potential source of free radicals in the ischaemic-reperfused myocardium. Eur Heart J 11(9):800–813Google Scholar
- 15.Moorhead K, Capelli B, Cysewski G (2005) Nature’s superfood: spirulina. Cyanotech Corporation, Kailua-Kona, HI, USA. ISBN #0-9637511-3-1Google Scholar
- 16.Ben-Amotz A, Mokady S, Edelstein A, Avron M (1989) Bioavailability of a natural isomer mixture as compared with synthetic all-trans-beta-carotene in rats and chicks. J Nutr 119(7):1013Google Scholar
- 17.Ben-Amotz A, Levy Y (1996) Bioavailability of a natural isomer mixture compared with synthetic all-trans betacarotene in human serum. Am J Clin Nutr 63(5):729–734Google Scholar
- 20.European Commission Health & Consumer Protection Directorate-General (2002) Opinion of the Scientific Committee on Animal Nutrition on the use of canthaxanthin in feeding stuffs for salmon and trout, laying hens, and other poultry. European Commission. http://ec.europa.eu/food/fs/sc/scan/out81_en.pdf. Accessed 20 December 2012Google Scholar